This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fujita, Y. Articles by Tanigawa, N. Search for Related Content PubMed PubMed Citation Articles by Fujita, Y. Articles by Tanigawa, N.

Proteomics-Based Approach Identifying Autoantibody against Peroxiredoxin VI as a Novel Serum Marker in Esophageal Squamous Cell Carcinoma

Authors' Affiliations: Departments of ¹ General and Gastroenterological Surgery and ² Clinical Pathology, Osaka Medical College, Osaka, Japan

Requests for reprints: Nobuhiko Tanigawa, Department of General and Gastroenterological Surgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686, Japan. Phone: 81-72-683-1221; Fax: 81-72-685-2057; E-mail: sur001{at}poh.osaka-med.ac.jp.

Purpose: Detection of novel tumor-related antigens and autoantibodies will aid in diagnosis of early-stage cancer and in development of more effective immunotherapies. The purpose of this study was to identify novel tumor antigens in an esophageal squamous cell carcinoma (ESCC) cell line (TE-2) and related autoantibodies in sera from patients with ESCC using a proteomics-based approach.

Experimental Design: TE-2 proteins were separated by two-dimensional PAGE, followed by Western blot analysis in which sera of patients with ESCC, healthy controls, and patients with other cancers were tested for primary antibodies. Positive spots were excised from silver-stained gels and analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/TOF MS).

Results: Sera from patients with ESCC yielded multiple spots, one of which was identified as peroxiredoxin (Prx) VI by MALDI-TOF/TOF MS. Western blot analysis against recombinant Prx VI showed reactivity in sera from 15 of 30 (50%) patients with ESCC and 2 of 30 (6.6%) healthy individuals. Autoantibody against Prx VI was found in sera from 1 of 30 (3.3%) patients with other types of cancer (colon cancer).

Conclusion: We have identified for the first time an autoantibody against Prx VI in ESCC patients. The proteomic approach implemented here offers a powerful tool for identifying novel serum markers that may display clinical usefulness against cancer.

This article has been cited by other articles:

				J. K. Yi, J. W. Chang, W. Han, J. W. Lee, E. Ko, D. H. Kim, J.-Y. Bae, J. Yu, C. Lee, M.-H. Yu, et al. Autoantibody to Tumor Antigen, Alpha 2-HS Glycoprotein: A Novel Biomarker of Breast Cancer Screening and Diagnosis Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1357 - 1364. [Abstract] [Full Text] [PDF]

				K. Ueda, T. Nakanishi, A. Shimizu, T. Takubo, and N. Matsuura Identification of L-plastin autoantibody in plasma of patients with non-Hodgkin's lymphoma using a proteomics-based analysis Ann Clin Biochem, January 1, 2008; 45(1): 65 - 69. [Abstract] [Full Text] [PDF]